EIKN (NASDAQ:EIKN) Upgraded at Wall Street Zen

EIKN (NASDAQ:EIKN) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Other equities analysts have also recently issued research reports about the stock. Zacks Research raised shares of EIKN to a “hold” rating in a research note on Friday, February 27th. Wedbush began coverage on shares of EIKN in a report on Thursday, February 26th. They issued an “underperform” rating and a $7.00 price objective for the company. JPMorgan Chase & Co. started coverage on shares of EIKN in a research note on Monday, March 2nd. They set an “overweight” rating and a $29.00 price objective on the stock. Bank of America assumed coverage on EIKN in a report on Monday, March 2nd. They set a “buy” rating and a $34.00 target price on the stock. Finally, Morgan Stanley initiated coverage on EIKN in a research report on Monday, March 2nd. They issued an “overweight” rating and a $32.00 target price for the company. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, EIKN currently has a consensus rating of “Moderate Buy” and an average price target of $25.60.

EIKN Price Performance

Shares of EIKN opened at $9.81 on Friday. EIKN has a one year low of $9.81 and a one year high of $17.40.

About EIKN

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.